HTRF® cell-based phospho and total-HER2 assays for anti-cancer research
Upregulation of HER2, human epidermoid receptor 2, also known as ErbB2 receptor is associated with human breast cancer and several others, such as ovarian, stomach, bladder, salivary or lung carcinomas, which makes HER2 a key target for anti-cancer therapies when screening or profiling small molecule tyrosine kinase inhibitors or biotherapeutic antibodies to induce ADCC or to block HER2 heterodimerization.
Cisbio’s homogeneous and robust HTRF® phospho-HER2 (Tyr1221/1222) assay kit is designed for the cell-based quantitative detection of HER2 signaling activity. The HTRF® total HER2 assay kit is designed for the quantitative detection of total HER2, phosphorylated and unphosphorylated, to normalize the phosphorylation status of HER2.
The buffers of both HTRF® phospho- and total HER2 assays are compatible, enabling an analysis of the phosphorylated and the total protein populations from one lysate sample.